bluebird bio, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
BLUE Company Description
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
BLUE Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view BLUE Smart Score
Score Breakdown
BLUE Company Description
Show More
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of BLUE by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BLUE's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on BLUE's company Twitter account
WallStreetBets
Number of mentions of BLUE in WallStreetBets Daily Discussion
BLUE News
Recent insights relating to BLUE
CNBC Recommendations
Recent picks made for BLUE stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in BLUE
Corporate Flights
Flights by private jets registered to BLUE
Our Analysis